Image

Lupus Landmark Study: A Prospective Registry and Biorepository

Recruiting
18 - 110 years of age
Both
Phase N/A

Powered by AI

Overview

The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).

Description

This is a multicenter registry and biorepository conducted in the United States (US) and Canada. The registry will enroll over 3500 individuals with SLE over the course of five years into one of following four cohorts:

  • New Onset: individuals with a new diagnosis of SLE
  • Active Lupus Nephritis: individuals with a recent diagnosis of LN
  • Extra-Renal Lupus Flare: individuals who have experienced a recent flare
  • Prevalent Cases: individuals with lupus who do not meet the criteria for one of the other cohorts

The registry data will include but is not limited to: patient demographics, medical history, clinician-reported outcomes (ClinROs), patient-reported outcomes (PROs), social history and determinants of health, and environmental exposures. Participants will also be asked to allow access to their medical records.

Biological samples, including whole blood, urine, saliva, stool and tissue will be collected throughout the study. These biospecimens will be used for a broad range of analyses, including genetics, genomics, proteomics, biomarker discovery and microbiome profiling.

Eligibility

Inclusion Criteria:

  • Able to understand and comply with study procedures and voluntarily sign a written informed consent document
  • Age 18 years or older at the time of enrollment
  • Fulfill criteria for SLE based on one or more of the following classifications
    systems
        Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 criteria;
        European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology
        (ACR) 2019 criteria; 1997 revised ACR criteria; or Lupus is present per clinical
        assessment.
        Exclusion Criteria:
          -  Not able to obtain consent
          -  Not able to meet protocol visit requirements
          -  Pregnant at the time of enrollment

Study details

Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus

NCT05934149

Lupus Research Alliance

27 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.